drugset / Trial / NCT05292417
Radiotherapy in Combination With Sintilimab，GM-CSF and Fruquintinib in Patients With MSS mCRC
NaSingle-groupOpen-labelTreatment
Summary
To evaluate the clinical efficacy and safety of hypofractionation radiotherapy combined with sintilimab，GM-CSF and Fruquintinib in Patients With MSS Metastatic Colorectal Carcinoma (mCRC)
Timeline
- Start
- 2022-03-25
- Primary completion
- 2023-03
- Completion
- 2024-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Fruquintinib | Small molecule | 5 mg | — |
| Subject | Sintilimab | Monoclonal antibody | 200 mg | Intravenous |
| Subject | sargramostim | Protein / enzyme biologic | 200 ug | — |